Vertex pharmaceuticals inc / ma (VRTX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Revenues:
Revenues:
Revenues

4,162

3,047

2,488

1,702

1,032

580

1,211

1,527

1,410

143

101

175

Costs and expenses:
Cost of sales

547

409

275

210

117

39

88

236

63

0

-

-

Royalty expenses

-

-

-

-

7

21

41

43

16

12

14

15

Research and development expenses

1,754

1,416

1,324

1,047

995

855

882

765

707

637

550

516

Sales, general and administrative expenses

658

557

496

432

376

305

356

432

400

187

130

101

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

4

0

0

-

-

-

-

-

-

-

-

-

Restructuring (income) expenses

0

-0

14

1

2

50

40

1

2

1

6

4

Intangible asset impairment charges

0

29

255

0

0

-

412

0

105

0

7

-

Acquisition-related expenses

-

-

-

-

-

-

-

-

-

-

7

-

Total costs and expenses

2,965

2,412

2,365

1,692

1,499

1,272

1,821

1,480

1,296

839

715

638

Income from operations

1,197

635

123

9

-466

-692

-610

46

113

-696

-614

-462

Interest income

63

38

11

-

-

-

-

-

-

1

5

16

Interest expense

58

72

69

-81

-84

-72

-22

-15

-37

19

13

13

Other income (expense), net

-

-

-

-

-

-

-

-

-

-41

-1

-

Other (expense) income, net

192

-0

-81

4

-6

30

6

0

-15

-

-

-

Loss on exchanges of convertible senior subordinated notes (due 2013)

-

-

-

-

-

-

-

-

-

-

-18

-

Income before provision for income taxes

1,394

600

-15

-67

-557

-734

-626

31

60

-754

-642

-

Provision for income taxes

218

-1,486

-107

16

30

6

-122

-0

19

0

-

-

Loss from continuing operations

-

-

-

-

-

-741

-503

32

-

-

-

-

Loss from discontinued operations, net of tax benefit of $0, $0 and $0, respectively

-

-

-

-

-

-0

-183

-83

-

-

-

-

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

1,176

2,087

91

-84

-588

-742

-687

-51

41

-754

-642

-459

(Income) loss attributable to noncontrolling interest

-

-

-

-

-

-4

0

0

-

-

-

-

Loss attributable to noncontrolling interest

0

-9

-171

28

-31

-

-242

55

11

0

-

-

Net Income (Loss) Attributable to Parent

1,176

2,096

263

-112

-556

-738

-445

-107

29

-754

-642

-

Loss from continuing operations

-

-

-

-

-

-737

-503

32

-

-

-

-

Loss from discontinued operations

-

-

-

-

-

-0

58

-139

-

-

-

-

Net loss from continuing operations:
Basic (usd per share)

-

-

-

-

-

-3.14

-2.24

0.15

-

-

-

-

Diluted (usd per share)

-

-

-

-

-

-3.14

-2.24

0.15

-

-

-

-

Net loss from discontinued operations:
Basic (usd per share)

-

-

-

-

-

0.00

0.26

-0.65

-

-

-

-

Diluted (usd per share)

-

-

-

-

-

0.00

0.26

-0.65

-

-

-

-

Earnings Per Share [Abstract]
Earnings Per Share, Basic

4.58

8.24

1.06

-0.46

-2.31

-3.14

-1.98

-0.50

0.14

-3.77

-3.71

-3.27

Earnings Per Share, Diluted

4.51

8.09

1.04

-0.46

-2.31

-3.14

-1.98

-0.50

0.14

-3.77

-3.71

-3.27

Shares used in per share calculations:
Weighted Average Number of Shares Outstanding, Basic

256

254

248

244

241

235

224

211

204

200

173

140

Weighted Average Number of Shares Outstanding, Diluted

260

259

253

244

241

235

224

215

208

200

173

140

Product revenues, net
Revenues

4,160

3,038

2,165

1,683

1,000

487

837

1,333

950

0

-

-

Collaborative and royalty revenues
Revenues

2

9

323

18

-

-

-

-

-

-

-

-

Royalty revenues
Revenues

-

-

-

-

23

40

156

141

50

30

28

37

Collaborative revenues
Revenues

-

-

-

-

8

51

217

52

409

113

73

138